Cagrilintide timeline: what the published trials and research reports show

Cagrilintide works on amylin and calcitonin receptors rather than GLP-1 directly, which is why it is usually studied alongside semaglutide rather than on its own. The published trial data covers both the standalone and combined arms.

What the published trials reported

This is trial-level data under medical supervision on pharmaceutical-grade product. It describes what the trials measured, not a personal outcome to expect from research use.

Weeks 1 to 4: the low doses

The published titration opens at 0.3 mg weekly. Reports at this stage tend to focus on mild GI effects and early appetite change, generally described as milder than what shows up with GLP-1 compounds alone at comparable trial stages.

Weeks 5 to 16: stepping toward the 2.4 mg target

The dose steps up roughly every four weeks. GI adverse events were reported in the trial for both the standalone and combined arms, generally described as transient and concentrated around dose increases.

Weeks 16 to 68: where the trial's numbers land

By week 68, the trial reported a clear separation between the cagrilintide-alone, semaglutide-alone and combined arms, with the combination consistently outperforming either compound on its own.

Common questions

Why is cagrilintide usually paired with semaglutide? The two act on complementary appetite pathways, amylin and GLP-1, and the published trial data shows the combination producing a larger effect than either alone.

Does the combined result mean the individual compounds are less useful? The trial still reports meaningful standalone results for both, the combination simply performed better in the same trial population.

For the full mechanism, titration schedule and citations, see the cagrilintide reference page.